CADTH

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Itch, Medication, Alagille syndrome, Liver disease, Inflammation, Patient, Cholestasis, Bile, Cholestatic pruritus, CADTH, Liver injury, The Hospital, Liver, CDEC, Genetic disorder, PFIC, Pharmaceutical industry

“The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.

Key Points: 
  • “The positive reimbursement recommendation for LIVMARLI by CADTH is an important step forward for patients suffering from the debilitating effects of cholestatic pruritus related to Alagille syndrome,” said Chris Peetz, chief executive officer at Mirum.
  • These patients suffer greatly from the debilitating and disruptive effects of Alagille syndrome, which often starts in early childhood.”
    “CADTH’s recommendation of reimbursement for LIVMARLI provides a meaningful advancement in the treatment of cholestatic pruritus for patients with Alagille syndrome.
  • LIVMARLI is also approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. and Europe, and for Progressive Familial Intrahepatic Cholestasis (PFIC) in the U.S. and in Europe.
  • Cholestasis in ALGS is associated with pruritus which is among the most common indications for liver transplant in ALGS.

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

Retrieved on: 
Monday, January 22, 2024
Patient, Knight Therapeutics, Agency, CADTH, Endo International, OTC, Epilepsy, Pharmaceutical industry

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Key Points: 
  • MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.
  • XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "We are pleased to announce the availability of XCOPRI in Canada," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "As a company dedicated to addressing unmet medical needs, we are committed to supporting the ongoing innovation in epilepsy management."
  • Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible.

Endo's Paladin Labs Announces Launch of XCOPRI® (cenobamate tablets) in Canada

Retrieved on: 
Monday, January 22, 2024
Patient, Knight Therapeutics, Agency, CADTH, Endo International, OTC, Epilepsy, Pharmaceutical industry

MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.

Key Points: 
  • MONTREAL, Jan. 22, 2024 /PRNewswire/ -- Paladin Labs Inc., a subsidiary of Endo International plc (OTC: ENDPQ), announced today that XCOPRI® (cenobamate tablets) is now available in Canada.
  • XCOPRI is indicated as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.
  • "We are pleased to announce the availability of XCOPRI in Canada," said Livio Di Francesco, Vice President & General Manager of Paladin Labs Inc. "As a company dedicated to addressing unmet medical needs, we are committed to supporting the ongoing innovation in epilepsy management."
  • Paladin Labs continues to work with federal, provincial, and territorial government payers across Canada and their negotiating body, the pan-Canadian Pharmaceutical Alliance, to help appropriate patients gain access to XCOPRI as soon as possible.

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Retrieved on: 
Thursday, November 2, 2023
DSM-IV codes, Faculty, Hypogonadism, BBS, BMI, Obesity, Life, CADTH, Prevalence, Health Canada, News, Deficit spending, Nausea, Bardet–Biedl syndrome, Priority review, Polyphagia, Visual impairment, Disease, Medicine, Body mass index, University, MC4R, University of Melbourne Faculty of Medicine, Dentistry and Health Sciences, Polydactyly, University of Alberta, Patient, Pharmaceutical industry, Health

BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended that IMCIVREE® (setmelanotide) be reimbursed by CADTH-participating public drug plans, with conditions, for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS).

Key Points: 
  • People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
  • BBS may also be associated with cognitive impairment, polydactyly, renal dysfunction, hypogonadism, and visual impairment.
  • “This recommendation represents a significant milestone for Canadian patients living with obesity due to BBS.
  • We appreciate CADTH’s recommendation and their recognition of the rare genetic nature of BBS, the unmet needs of these patients and that IMCIVREE is the only available therapy that targets the underlying disease mechanism of BBS,” said Carol Stiff, General Manager of Rhythm Pharmaceuticals Canada Inc.

Government of Canada announces new appointment to the Patented Medicine Prices Review Board

Retrieved on: 
Wednesday, October 25, 2023
Parliament, Democracy, Government of Canada, PMPRB, Government, CADTH, Patent Act, Research, Patented Medicine Prices Review Board, Patent Act (Canada), University, Canadian Agency for Drugs and Technologies in Health, Queen's University, Queen, Hospital, Patent, Pharmaceutical industry, Health, Crown

OTTAWA, ON, Oct. 25, 2023 /CNW/ - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices Review Board (PMPRB ).

Key Points: 
  • OTTAWA, ON, Oct. 25, 2023 /CNW/ - Today, the Honourable Mark Holland, Minister of Health, announced a new appointment to the Patented Medicine Prices Review Board (PMPRB ).
  • As an arm's-length organization of the government, the PMPRB protects the interests of Canadian consumers by ensuring that the prices of patented medicines sold in Canada are not excessive.
  • "For more than 35 years, the Patented Medicine Prices Review Board (PMPRB) has been charged with protecting Canadian consumers from excessive prices of patented drugs.
  • The PMPRB protects the interests of Canadian consumers by ensuring that the prices of patented medicines sold in Canada are not excessive.

INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec

Retrieved on: 
Monday, September 18, 2023
AOH, FRCP, Attack, Hereditary angioedema, BioCryst Pharmaceuticals, Doctor of Philosophy, RESEARCH, HAE, Patient, CADTH, Health Canada, PARK, Caregiver, Disease, Pharmaceutical industry

“While much progress has been made on behalf of the HAE community in Québec, people living with HAE continue to be in need of additional treatment options to help manage their HAE attacks.

Key Points: 
  • “While much progress has been made on behalf of the HAE community in Québec, people living with HAE continue to be in need of additional treatment options to help manage their HAE attacks.
  • Additionally, this recommendation is a step forward as it highlights the need for continued, and simple access for people living with HAE, and their caregivers,” said Charles St-Pierre, president of Hereditary Angioedema Québec (AOH Québec).
  • “As a physician who treats HAE patients, I see first hand how people respond to different HAE treatments, and not every patient’s experience is the same.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent HAE attacks in patients 12 years and older.

CCX appoints Blake Dark, former NHS chief negotiator, to advisory board

Retrieved on: 
Tuesday, May 16, 2023
Dark, Partnership, ISPOR, England, CCX, CADTH, Ecosystem, NHS, NICE, Software, Management, Pharmaceutical industry, Sanofi

ZUG, Switzerland and BOSTON, May 16, 2023 /PRNewswire-PRWeb/ -- CCX, the market access software leader, announced today that Blake Dark has joined the company's advisory board. With a deep understanding of both the constraints and possibilities in market access, Dark will advise on both the design of CCX's transformational platform and commercial strategy.

Key Points: 
  • Blake Dark, former NHS chief negotiator, joins other leaders from industry and payer to advise CCX as they build and deploy the technology stack for market access.
  • ZUG, Switzerland and BOSTON, May 16, 2023 /PRNewswire-PRWeb/ -- CCX, the market access software leader, announced today that Blake Dark has joined the company's advisory board.
  • "I'm very excited to support CCX and join such a prestigious group of advisors," said Blake Dark.
  • "I'm very pleased that Blake has joined the CCX advisory board.

CADTH Honours 2 Leaders for Outstanding Contributions to Health Technology Assessment in Canada

Retrieved on: 
Tuesday, May 16, 2023
Faculty, Agency, University, Research design, ISPOR, The Ottawa Hospital, React, Faculty of Pharmacy, University of Lisbon, HTA, Research, University of Ottawa Heart Institute, Language, International Network of Health Promoting Hospitals and Health Services, Associate, Science, Creativity, Organization, Public health, Patient, School, ISCB Senior Scientist Award, COVID-19 Response Recognition Award, ICES, Chiang Mai University, Medical device, Management, Nursing, Pharmacy, CADTH

OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.

Key Points: 
  • OTTAWA, ON, May 16, 2023 /CNW/ - Today, CADTH, Canada's drug and health technology agency, announced the recipients of its 2023 Recognition Awards.
  • These prizes honour individuals who are pushing the science of health technology assessment (HTA) forward, mentoring the next generation of leaders, and helping to grow Canada's reputation for excellence in the field.
  • Brian was a key member of the international joint task group convened by the International Network of Agencies for Health Technology Assessment to lead this work.
  • Dr. Kednapa Thavorn is at the forefront of this advancement in Canada, as both a methodologist and health economist.

CADTH Recommends Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Routine Prevention of Attacks in Hereditary Angioedema Patients in Canada

Retrieved on: 
Wednesday, March 8, 2023
MD, BioCryst Pharmaceuticals, PARK, Health Canada, Patient, CADTH, Disease, Hereditary angioedema, FRCPC, British Society of Cinematographers, HAE, CDEC, RESEARCH, Pharmaceutical industry, Health insurance

RESEARCH TRIANGLE PARK, N.C., March 08, 2023 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Canadian Agency for Drugs and Technologies in Health (CADTH) Canadian Drug Expert Committee (CDEC) has issued a positive recommendation for ORLADEYO® (berotralstat) to be reimbursed for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.

Key Points: 
  • In issuing this positive recommendation, CADTH is opening the door to many Canadian HAE patients being able to access ORLADEYO,” said Stephen Betschel, HBSc, MD, FRCPC, FAAAAI, Chair of the Canadian Hereditary Angioedema Network.
  • “BioCryst is delighted that ORLADEYO has received this positive recommendation from CADTH.
  • Health Canada authorized ORLADEYO in June 2022 for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.
  • The full CADTH reimbursement recommendation for ORLADEYO is available on CADTH’s website .

CADTH's 2023 Watch List Spotlights Precision Medicine Technologies and Issues

Retrieved on: 
Monday, March 6, 2023
Personalized medicine, Gene, Interpol Terrorism Watch List, News, CADTH, Growth, Environment, Medicine, Watchlist, Hope, Medical device, Journal of Nuclear Medicine Technology, Pharmaceutical industry

According to a newly published report from CADTH, these are among the top 5 health technologies to watch within precision medicine — an innovative approach to treatment and medicine that considers a person's unique genes, characteristics, and environment to inform and tailor their care.

Key Points: 
  • According to a newly published report from CADTH, these are among the top 5 health technologies to watch within precision medicine — an innovative approach to treatment and medicine that considers a person's unique genes, characteristics, and environment to inform and tailor their care.
  • These issues include disparities in access and use, increased demands on health system capacity and infrastructure, and challenges in regulating and evaluating these technologies.
  • The top 5 precision medicine technologies identified by CADTH are:
    The top 5 issues to watch are:
    CADTH's 2023 Watch List of the Top 10 Precision Medicine Technologies and Issues gives decision-makers a clear signal about 5 precision medicine technologies that are likely to shape the future of health care in Canada over the next 5 years and 5 issues that will affect their ongoing development and adoption.
  • To develop the report, a short list of emerging technologies and issues was identified from published literature and industry news with input from an expert advisory group.